Representative Matters
代表事项
REFERENZMANDATE
Venture Financings
- Sionna Therapeutics in its $111 million Series B financing
- Vedere Bio II in its $77 million Series A financing
- Triplet Therapeutics in its $49 million Series A financing
- Quentis Therapeutics in its $48 million Series A financing
- Cadent Therapeutics in its $40 million Series B financing
- Hodinkee in its $40 million Series B financing
- LeafLink in its $35 million Series B financing
- Alto Solutions in its $17 million Series A financing and $40 million Series B financing
- Noodle Partners in its $16 million Series B financing and $50 million Series C financing
- Bessemer Venture Partners’ investment in Papaya’s $50 million Series B financing
- Two Sigma Ventures’ investment in Remote Technology’s $11 million Series Seed financing
- Digital+ Partners’ investment in ChartIQ’s $17 million Series B financing
- Batu Capital Investments’ investment in MJ Freeway’s $10 million Series C financing
Mergers and Acquisitions
- LaSalle Hotel Properties in a $5.2 billion merger with Pebblebrook Hotel Trust
- TripleLift in its $1.4 billion acquisition by Vista Equity Partners
- Kensho Technologies in its $550 million acquisition by S&P Global
- Lennar Corporation in the sale of its SunStreet solar platform to Sunnova Energy
- Johnson & Johnson in the sale of its BabyCenter business to Everyday Health Group
- TARA Biosystems in its acquisition by Valo Health
- Plug Power in its $58 million acquisition of Giner ELX, Inc.
- Plug Power in its $65 million acquisition of United Hydrogen Group Inc.
- Vedere Bio in its $280 million acquisition by Novartis
- OncoImmune in its $425 million acquisition (plus undisclosed milestone payments) by Merck
Strategic Alliances and Collaborations
- Arrakis in its research collaboration agreement with Amgen on the discovery and development of RNA degrader therapeutics, with an upfront of $75 million and up to several billion dollars in potential milestones and royalties
- Amathus Therapeutics on its strategic collaboration with Merck to develop novel small molecule therapeutic candidates for neurodegenerative diseases, for an upfront payment and milestone payments associated with the successful development candidates in excess of $500 million per program
Public Offerings
- SpringWorks Therapeutics, Inc. in its $186.3 million initial public offering
- Cowen and Company and William Blair as underwriters in a $32.5 million follow-on offering for Ovid Therapeutics Inc.
- Oppenheimer & Co. Inc. as underwriters in a $15.4 million follow-on public offering for BioLineRx, Inc.
- Stifel, Nicolaus & Company as underwriters in a $11.5 million follow-on public offering for IRIDEX Corporation
Professional Activities
Mr. Hays serves as the New York Co-Chair of Goodwin’s Neighborhood Business Initiative (NBI), a program created to provide pro bono legal services to low-income entrepreneurs and small business owners in underserved communities.
Mr. Hays is a member of the Board of Directors of the scientific research institute PSE Healthy Energy (Physicians, Scientists & Engineers) and a member of the Board of Directors of Artists with Evidence, a nonprofit that commissions artists and scientists to collaborate, explore and exhibit art works.Professional Experience
Prior to joining Goodwin, Mr. Hays served as the Director of the Environmental Health Program at PSE Healthy Energy and as a research associate at Weill Cornell Medicine.